Bill > AJR155

This Joint Resolution establishes the New Jersey Pharmacogenomics Commission, a 13-member body tasked with studying pharmacogenomics, which is the science of how a person's unique genetic makeup influences their response to medications, including their effectiveness and potential side effects. The commission will investigate various aspects of pharmacogenomics, such as its costs, benefits for patients and healthcare providers, applications beyond traditional medicine like addressing the opioid crisis, its role in personalized medicine, and how to educate the public and medical professionals about its use. The commission's members will represent various state departments, universities with medical and pharmacy programs, and professional organizations, with appointments made by the Governor, Senate President, and Assembly Speaker. The commission is required to hold public hearings in both northern and southern New Jersey and will submit a comprehensive report of its findings and recommendations to the Governor and Legislature before it expires.